Bionomics Limited

101 articles with Bionomics Limited

• Further Data Analysis of Bionomics’ Phase 2 Post Traumatic Stress Disorder Trial Shows the Potential for Significant Patient Benefit When Drug Exposure Is Adequate

  2/18/2019

  Bionomics Limited announces that an additional data analysis conducted in Sweden by Pharmetheus AB showed a statistically significant response when drug exposure versus response was measured in the Phase 2 PTSD Trial.

• 

  Bionomics Announces that BNC210 Doesn’t Treat PTSD Symptoms

  10/3/2018

  Yesterday, top-line data from Bionomics Limited revealed details of the biopharmaceutical company’s Phase II clinical trial of BNC210 in regards to patients with post traumatic stress disorder. 

• Bionomics’ Phase 2 Post Traumatic Stress Disorder Trial Results

  10/2/2018

  Trial did not meet primary endpoint of decrease in PTSD symptoms as measured by CAPS-5 at 12 weeks

• Commencement of BNC210 Phase 2 Clinical Trial for the Treatment of Agitation

  5/24/2018

  Treatment of agitation in the elderly in hospital and nursing home settings represents a rapid potential path to market for BNC210 No currently approved treatments and significant unmet medical need

• Bionomics Limited: A Company With Deals On The Horizon

  7/5/2017

• Bionomics Limited Release: New BNC105 Clinical Trial In Combination With Keytruda

  2/20/2017

• Bionomics Limited To Receive Milestone Payment From Merck & Co. For Initiation Of Phase I Clinical Study Of Candidate Alzheimer's Treatment

  2/3/2017

• Bionomics Limited Announces Positive Results From Phase 2 Trial Of BNC210 In Generalized Anxiety Disorder

  9/21/2016

• Bionomics Limited Release: Post Traumatic Stress Disorder Identified As Major New Market Opportunity For BNC210

  12/8/2015

• Bionomics Limited And MSD Hosting Cognition And Alzheimer's Symposium Featuring Australian And US Speakers

  11/13/2015

• Bionomics Limited To Present Preclinical Data On BNC105 At AACR-NCI-EORTC International Conference

  11/4/2015

• Bionomics Limited Announces Extension Of Strategic Collaboration With Merck & Co. For The Discovery And Development Of Novel Pain Medications

  10/8/2015

• Bionomics Limited Reports Positive Data From Phase 1 Multiple Ascending Dose Trial Of BNC210 For Anxiety And Depression

  9/16/2015

• Bionomics Limited Release: Successful BNC101 IND Submission Paves Way For Development Of Promising Cancer Stem Cell Drug Candidate

  8/31/2015

• Bionomics Limited Files Patent For Use Of BNC105 In Combination With PD-1 And CTLA-4 Immuno-Oncology Antibodies

  6/15/2015

• Bionomics Limited Initiates Phase II Clinical Trial Of BNC210 For Treatment Of Anxiety

  4/20/2015

• Bionomics Limited Showcases Oncology Drug Development Programs At 2015 American Association for Cancer Research Annual Meeting

  4/17/2015

• Bionomics Limited Release: BNC105 Biomarker Data To Be Presented At Asian Oncology Conference

  4/10/2015

• Bionomics Limited Begins Trading On OTCQX Marketplace

  3/2/2015

• Bionomics Limited Release: New BNC105 Biomarker Data To Be Presented At US Cancer Conference

  2/27/2015